Fielmann Group AG (FLMNF)
OTCMKTS · Delayed Price · Currency is USD
60.22
0.00 (0.00%)
Dec 12, 2025, 9:30 AM EST
Fielmann Group AG Revenue
Fielmann Group AG had revenue of 620.18M EUR in the quarter ending September 30, 2025, with 2.73% growth. This brings the company's revenue in the last twelve months to 2.42B, up 12.00% year-over-year. In the year 2024, Fielmann Group AG had annual revenue of 2.26B with 14.88% growth.
Revenue (ttm)
2.42B EUR
Revenue Growth
+12.00%
P/S Ratio
1.48
Revenue / Employee
99.18K EUR
Employees
24,363
Market Cap
4.19B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.26B | 293.22M | 14.88% |
| Dec 31, 2023 | 1.97B | 211.85M | 12.04% |
| Dec 31, 2022 | 1.76B | 80.90M | 4.82% |
| Dec 31, 2021 | 1.68B | 249.22M | 17.44% |
| Dec 31, 2020 | 1.43B | -91.81M | -6.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
Fielmann Group AG News
- 27 days ago - Fielmann Group AG (FLMNF) Q3 2025 Earnings Call Highlights: Strong Profitability Amidst Mixed ... - GuruFocus
- 3 months ago - Fielmann Group AG (FLMNY) Analyst/Investor Day - Slideshow - Seeking Alpha
- 6 months ago - Fielmann: Margin Recovery Likely, But Still Not Priced In - Seeking Alpha